Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study - Khodaverdian, Verjine; Tapadar, Subhasish; MacDonald, Ian A.; Xu, Yuan; Ho, Po-Yi; Bridges, Allison; Rajpurohit, Pragya; Sanghani, Bhakti A.; Fan, Yuhong; Thangaraju, Muthusamy; Hathaway, Nathaniel A.; Oyelere, Adegboyega K. (Scientific reports, 2019)
Keywords: 631/154/309/2420; 631/67/1347; 82; Animal models; Animals; Antitumor agents; Breast cancer; Catalytic Domain - drug effects; Cell Line, Tumor; Chelates; Chelation; Chromatin; Cytotoxicity; Deferiprone - pharmacology; Demethylation; DNA Methylation - drug effects; Enzyme Assays; Enzyme Inhibitors - pharmacology; Enzyme Inhibitors - therapeutic use; Female; Gene silencing; Histone Code - drug effects; Histone Demethylases - antagonists & inhibitors; Histone Demethylases - chemistry; Histones - metabolism; Humanities and Social Sciences; Humans; Inhibitory Concentration 50; Iron; Lysine; Mice; Molecular Docking Simulation; multidisciplinary; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - pathology; Recombinant Proteins - metabolism; Reductase; Ribonucleotide reductase; Science; Science (multidisciplinary); Structure-Activity Relationship; Tumor cell lines; Xenograft Model Antitumor Assays; Xenografts